Literature DB >> 15543634

Verification bias-corrected estimators of the relative true and false positive rates of two binary screening tests.

Todd A Alonzo1.   

Abstract

The relative accuracy of two binary screening tests can be quantified by estimating the relative true positive rate (rTPR) and relative false positive rate (rFPR) between the two tests. Ideally all study subjects are administered both screening tests as well as a gold standard to determine disease status. In practice, however, often the gold standard is so invasive or costly that only a percentage of study subjects receive disease verification and the percentage differs depending on the results of the two screening tests. This is known as verification-biased sampling and may be by design or due to differential patient dropout or refusal to have the gold standard test administered. In this paper, maximum likelihood estimators of rTPR and rFPR and corresponding confidence intervals are developed for studies with verification-biased sampling assuming that disease status is missing at random (MAR). Simulation studies are used to show that if the MAR assumption holds, then the verification bias-corrected point estimators have little small sample bias and the confidence intervals have good coverage probabilities. Simulation studies also demonstrate that the verification bias-corrected point estimators may not be robust to violation of the MAR assumption. The proposed methods are illustrated using data from a study comparing the accuracy of Papanicolaou and human papillomavirus tests for detecting cervical cancer. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2005        PMID: 15543634     DOI: 10.1002/sim.1959

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

Review 1.  Clinical application of DNA ploidy to cervical cancer screening: A review.

Authors:  David Garner
Journal:  World J Clin Oncol       Date:  2014-12-10

2.  A new method to address verification bias in studies of clinical screening tests: cervical cancer screening assays as an example.

Authors:  Xiaonan Xue; Mimi Y Kim; Philip E Castle; Howard D Strickler
Journal:  J Clin Epidemiol       Date:  2013-12-12       Impact factor: 6.437

3.  Estimating the agreement and diagnostic accuracy of two diagnostic tests when one test is conducted on only a subsample of specimens.

Authors:  Hormuzd A Katki; Yan Li; David W Edelstein; Philip E Castle
Journal:  Stat Med       Date:  2011-12-04       Impact factor: 2.373

Review 4.  Estimation of diagnostic test accuracy without full verification: a review of latent class methods.

Authors:  John Collins; Minh Huynh
Journal:  Stat Med       Date:  2014-06-09       Impact factor: 2.373

5.  Bias in trials comparing paired continuous tests can cause researchers to choose the wrong screening modality.

Authors:  Deborah H Glueck; Molly M Lamb; Colin I O'Donnell; Brandy M Ringham; John T Brinton; Keith E Muller; John M Lewin; Todd A Alonzo; Etta D Pisano
Journal:  BMC Med Res Methodol       Date:  2009-01-20       Impact factor: 4.615

6.  Reducing decision errors in the paired comparison of the diagnostic accuracy of screening tests with Gaussian outcomes.

Authors:  Brandy M Ringham; Todd A Alonzo; John T Brinton; Sarah M Kreidler; Aarti Munjal; Keith E Muller; Deborah H Glueck
Journal:  BMC Med Res Methodol       Date:  2014-03-05       Impact factor: 4.615

7.  Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study.

Authors:  Hans Ikenberg; Christine Bergeron; Dietmar Schmidt; Henrik Griesser; Francisco Alameda; Claudio Angeloni; Johannes Bogers; Roger Dachez; Karin Denton; Jalil Hariri; Thomas Keller; Magnus von Knebel Doeberitz; Heinrich H Neumann; Luis M Puig-Tintore; Mario Sideri; Susanne Rehm; Ruediger Ridder
Journal:  J Natl Cancer Inst       Date:  2013-10-04       Impact factor: 13.506

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.